title: [Aldosterone receptor antagonists].
abstract: Mineralocorticoid signaling pathway plays a pivotal role in cardiovascular physiopathology. Evidences from clinical and experimental studies have linked mineralocorticoid hormones with cardiovascular morbiditiy and mortality. Thus, antagonist of the mineralocorticoid receptor (AMR) has reappeared. In addition, a novel mineralocorticoid receptor antagonist has been developped, named eplerenone, which lack the side effect of former ARMs as gynecomastia. Based on two studies named RALES et EPHESUS, guidelines of the european and american societies of cardiology recommend the use of ARMs as a treatment for cardiac failure NYHA III and IV, and post-infarct cardiac failure (ejection fraction < 40%).
authors.affiliation: Service de cardiologie, CHUV, 1011 Lausanne. olivier.muller@chuv.ch
authors.forename: O
authors.initials: O
authors.lastname: Muller
authors.forename: D
authors.initials: D
authors.lastname: Firsov
authors.forename: C
authors.initials: C
authors.lastname: Seydoux
mesh_terms: D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists; D018161:Receptors, Mineralocorticoid / Q000502:physiology; D015398:Signal Transduction
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D018161:Receptors, Mineralocorticoid